Speakers

Dr. Rong Wang is currently the Associate Director in the Division of Bioequivalence I (DBI), Office of Bioequivalence (OB), Office of Generic Drugs (OGD). Dr. Wang began her regulatory science career at FDA in 2010. Over the span of her 13 years of working in OGD, Dr. Wang has served as a primary, secondary and tertiary assessor of abbreviated new drug applications (ANDAs), Control Correspondences (CCs), Protocols and other regulatory submissions to the FDA related to generic drug products. She has also been actively involved in various working groups within the Agency where she has contributed her expertise and experiences in revising or developing general guidance for ANDAs and establishing work process for ANDA assessment. Dr. Wang received her undergraduate degree in pharmacy from Shanghai Medical University and her Ph.D. in Microbial and Biochemical Pharmaceutical Science from Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College in China. Dr. Wang also earned her Pharm.D. from University of Florida.